Novo Nordisk to start phase III trial with tablet for Alzheimer's

Novo Nordisk plans to start a phase III trial with semaglutide against Alzheimer's disease during the first half of 2021, states the firm in a company announcement.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN

After many external research results with GLP-1 drugs used to treat Alzheimer's disease have been publicly presented, Novo Nordisk has opted to initiate its own research program, which the pharmaceutical company states on Wednesday afternoon in a company announcement.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading